Objective To investigate the effect of intravenous thrombolysis by recombinant human tissue fibrinogen activator on neurological function in elderly patients with acute cerebral infarction.
Methods The clinical data of 60 elderly patients with acute cerebral infarction in our hospital were retrospective analyzed. The patients were divided into study group (n=30, intravenous thrombolysis using recombinant human tissue fibrinolysin activator) and control group (n=30, routine treatment only) according to the treatment methods. The therapeutic effects were compared.
Results The NIHSS scores of the study group at 1, 7 and 14 d of treatment were all lower than those of the control group (P < 0.05). The favorable prognosis rate in the study group was higher than that in the control group at 90 d after the onset(70.00% vs. 43.33%, P < 0.05). There was no significant difference in the incidence of adverse events between the two groups (P>0.05).
Conclusion Intravenous thrombolytic therapy with recombinant human tissue fibrinolysin activator can improve neurological function and prognosis without increasing the risk of adverse events for elderly patients with acute cerebral infarction.
DownLoad: